REVIEW

Macrophage nuclear receptors: Emerging key players in infectious diseases

Chrissy M. Leopold Wager, Eusondia Arnett, Larry S. Schlesinger* *
Texas Biomedical Research Institute, San Antonio, Texas, United States of America
* lschlesinger@txbiomed.org

Abstract

Nuclear receptors (NRs) are ligand-activated transcription factors that are expressed in a variety of cells, including macrophages. For decades, NRs have been therapeutic targets because their activity can be pharmacologically modulated by specific ligands and small molecule inhibitors. NRs regulate a variety of processes, including those intersecting metabolic and immune functions, and have been studied in regard to various autoimmune diseases. However, the complex roles of NRs in host response to infection are only recently being investigated. The NRs peroxisome proliferator-activated receptor γ (PPARγ) and liver X receptors (LXRs) have been most studied in the context of infectious diseases; however, recent work has also linked xenobiotic pregnane X receptors (PXRs), vitamin D receptor (VDR), REV-ERBα, the nuclear receptor 4A (NR4A) family, farnesoid X receptors (FXRs), and estrogen-related receptors (ERRs) to macrophage responses to pathogens. Pharmacological inhibition or antagonism of certain NRs can greatly influence overall disease outcome, and NRs that are protective against some diseases can lead to susceptibility to others. Targeting NRs as a novel host-directed treatment approach to infectious diseases appears to be a viable option, considering that these transcription factors play a pivotal role in macrophage lipid metabolism, cholesterol efflux, inflammatory responses, apoptosis, and production of antimicrobial byproducts. In the current review, we discuss recent findings concerning the role of NRs in infectious diseases with an emphasis on PPARγ and LXR, the two most studied. We also highlight newer work on the activity of emerging NRs during infection.

Introduction

Nuclear receptors (NRs) comprise a superfamily of intracellular transcription factors that are key players in macrophage homeostasis, metabolism, and transcriptional regulation [1–5]. NRs are activated upon interaction with specific ligands, which are typically lipid-soluble and membrane-permeable. Macrophages use NRs to sense their local environment, shaping their immune response. There are 48 NRs in the human genome [6] and 49 in the rodent genome, of which 28 are associated with macrophages [7] (see Table 1 for selected members). Members of the NR superfamily have historically been categorized into three classes: conventional steroid/thyroid hormone receptors (e.g., estrogen receptor, progesterone receptor), orphan
receptors for which the ligand has either not been identified or that appear to function without a ligand, and adopted orphan receptors for which a ligand has been discovered (e.g., liver X receptors [LXRs], peroxisome proliferator-activated receptors [PPARs], and retinoid X receptors [RXRs]) [8].

In the United States, approximately $70 billion was spent to treat infectious diseases in 2013, and the cost per case for treatment grew the fastest compared to other diseases between 2000 and 2013 [9]. With the dramatic increase in the prevalence of pathogens becoming resistant to existing therapeutics that target the microorganism (antibiotics, antivirals, antiparasitics, etc.), it is critical to consider novel host-directed therapeutics (HDTs) to assist in combating infectious diseases. Approximately 13% of drugs approved for sale in the US target NRs and represented $27.5 billion in sales revenue in 2009 [10]. Drugs targeting NRs are

### Table 1. Select NR family members. List of some commonly studied NRs.

| Classification            | Group                               | Abbreviation | NRNC symbol | Gene   | Endogenous ligands         |
|---------------------------|-------------------------------------|--------------|-------------|--------|-----------------------------|
| Steroid hormone receptors | Thyroid hormone receptor            | THRα         | NR1A1       | THRA   | Thyroid hormones            |
|                           |                                     | THRβ         | NR1A2       | THRB   |                             |
| Retinoic acid receptor    | RARα                                 | RARA         |             |        | Retinoid acids              |
|                           | RARβ                                 | RARB         |             |        |                             |
|                           | RARγ                                 | RARG         |             |        |                             |
| Glucocorticoid receptor   | GR or GCR                            | NR3C1        |             | NR3C1  | Glucocorticoids             |
| Vitamin D receptor        | VDR                                  | NR1I1        |             | VDR    |                             |
| Adopted orphan receptors  | Peroxisome proliferator-activated receptor | PPARα      | NR1C1       | PPARA  | Fatty acids                 |
|                           |                                     | PPARβ/δ     | NR1C2       | PPARD  |                             |
|                           |                                     | PPARγ       | NR1C3       | PPARG  |                             |
|                           | REV-ERB                              | REV-ERβα    | NR1D1       | NR1D1  |                             |
|                           |                                     | REV-ERββ    | NR1D2       | NR1D2  |                             |
| Liver X receptor          | LXRα                                 | NR1H3       |             | NR1H3  | Oxysterols                  |
|                           | LXRβ                                 | NR1H2       |             | NR1H2  |                             |
| Farnesoid X receptor      | FXR                                   | NR1H4       |             | NR1H4  | Bile acids                  |
| Pregnane X receptor       | PXR                                  | NR1I2       |             | NR1I2  | Xenobiotics                 |
| Retinoid X receptor       | RXRα                                 | NR2B1       |             | RXRA   |                             |
|                           | RXRβ                                 | NR2B2       |             | RXRB   | 9-cis retinoic acid         |
|                           | RXRγ                                 | NR2B3       |             | RXRG   |                             |
| Orphan receptors          | RAR-related orphan receptor          | RORA        | NR1F1       | RORA   |                             |
|                           |                                     | RORB        | NR1F2       | RORB   |                             |
|                           |                                     | RORC        | NR1F3       | RORC   |                             |
| Testicular receptor       | TR2                                  | NR2C1       |             | NR2C1  |                             |
|                           | TR4                                  | NR2C2       |             | NR2C2  |                             |
| Estrogen-related receptor | ERRα                                 | NR3B1       |             | ESRRA  |                             |
|                           | ERRβ                                 | NR3B2       |             | ESRRB  |                             |
|                           | ERRγ                                 | NR3B3       |             | ESRRG  |                             |
| NR4A family               | Nur77                                 | NR4A1       |             | NR4A1  |                             |
|                           | Nur1                                 | NR4A2       |             | NR4A2  |                             |
|                           | Nor1                                 | NR4A3       |             | NR4A3  |                             |
| Liver receptor homolog-1  | LRH-1                                 | NR5A2       |             | NR5A2  |                             |

*NRs recently shown to influence macrophage responses to pathogenic microbes that are discussed in this review. Some synthetic and/or endogenous ligands have been suggested for certain orphan receptors, however they have not yet been confirmed.

**Abbreviations:** NR, nuclear receptor; NRNC, nuclear receptor nomenclature committee; NR4A, nuclear receptor 4A; RAR, retinoic acid receptor.

https://doi.org/10.1371/journal.ppat.1007585.t001
typically used to treat diabetes, atherosclerosis, and autoimmune diseases. However, NRs are becoming increasingly appreciated in the context of infections; therefore, targeting NRs may provide a new, largely unexplored area for infectious disease treatment.

NRs: Structure and function
NRs have a common architecture, containing an N-terminal transactivation domain, a highly conserved DNA-binding domain and a carboxy-terminal ligand-binding domain (reviewed in [11], Fig 1). NRs are activated following binding to the receptor’s specific ligand. The NR then undergoes a conformational change which can lead to recruitment of coactivators and/or corepressors [12]. NRs can exist as monomers, homodimers, or heterodimers (often with RXR) and can positively regulate transcription by binding to specific response elements of their target genes. NRs can also regulate transcription by repression or trans-repression [3–5] and inhibition of other transcription factors like nuclear factor kappa B (NF-kB) (reviewed in [8]). NR activity and stability can be further regulated by post-translational modifications (i.e., phosphorylation, acetylation, sumoylation, and ubiquitination) [13].

NRs and macrophage inflammatory responses
Macrophages have numerous, diverse roles in the host and are typically regarded as capable of activating to a pro-inflammatory, antimicrobial phenotype or an anti-inflammatory, wound-healing phenotype that does not efficiently kill microbes [14–17]. However, macrophage activation is now viewed as a spectrum rather than two distinct polarization states (e.g., M1 or M2), and many macrophages exhibit a mixed phenotype dependent on numerous factors in the local tissue environment [14, 18–24].

NRs are intimately involved in macrophage development as well as in macrophage inflammatory response and host defense pathways. PPARγ repeatedly appears as a regulator of alveolar macrophage (AM) development and polarization [25–28], and LXRα is required for maturation of Kupffer cells (liver-resident macrophages) and differentiation of macrophages in the marginal zone of the spleen [29, 30]. In AMs, PPARγ is constitutively expressed at high levels, contrasting with its expression in blood and other tissue macrophages [28, 31, 32].

PPARγ expression in AMs is important for inhibiting Th1-type pro-inflammatory responses, resolution of inflammation, and for maintaining homeostasis in murine lungs [28, 33]. PPARγ is also important for expansion of hematopoietic stem cells from cord blood in humans but not in mice [34]. The Th2-associated cytokine interleukin-4 (IL-4) augments PPARγ expression, induces the generation of PPARγ ligands, and contributes to the maturation of M2 macrophages [35, 36]. Recent studies have identified protein arginine methyltransferase 1 (PRMT1) as a critical enzyme for PPARγ’s responsiveness to IL-4 due to the asymmetric demethylation of histone H4 arginine 3 at the PPARγ promoter [37]. This study also revealed PRMT1’s importance for the transition from monocyte to macrophage. A recent study showed that PPARγ is recruited to the genome in a ligand-independent manner during polarization with IL-4 in murine macrophages [38]. Upon repeated IL-4 exposure, ligand-insensitive PPARγ established a permissive chromatin environment that conferred transcriptional memory preferential to the M2 polarization state and resistance to IFN-γ stimulation [38]. This study revealed a PPARγ-mediated mechanism for memory-like responses in macrophages independent of ligand binding.

Several other NRs play significant roles in macrophage inflammatory responses. For example, many genes inhibited by LXR agonists are targets of NF-kB [39], indicating an inhibitory effect of LXR on pro-inflammatory responses. REV-ERBα is expressed in primary human macrophages and is induced by LXR [40]. REV-ERBα is a constitutive repressor that is more
highly expressed in M1- compared to M2-activated human macrophages, repressing IL-10 production [41]. In murine macrophages, a REV-ERBα agonist suppressed transcription of IL-6 and C-C motif chemokine ligand 2 (CCL-2), as well as the CCL-2 activated signals extracellular signal-regulated kinase (ERK) and p38 [42, 43], indicating that this NR’s anti-inflammatory actions are conserved between species. Another family of NRs, the NR4A family, is also expressed in several macrophage models, and family members are up-regulated in response to inflammatory stimuli such as lipopolysaccharide (LPS) or tumor necrosis factor α.
(TNF-α), promoting anti-inflammatory, M2-like macrophage responses [44–49]. NR regulation of macrophage inflammatory responses are reviewed in more detail elsewhere [1, 4, 5, 7, 8, 50]. In this review, we discuss recent literature regarding NRs shown to influence macrophage responses in infectious diseases.

**PPARs**

PPAR activities in macrophages are important for the control of transport, synthesis, activation, and oxidation of fatty acids [2]. Mammals have three PPAR subtypes: PPARα, PPARγ, and PPARβ/δ (also referred to as NR1C1, NR1C3, and NR1C2, respectively; Table 1). The subtypes exhibit diverse expression patterns and functions. PPARα and PPARγ are expressed in macrophages and are important players in macrophage inflammatory responses [36, 51, 52]. Earlier studies examining the complex relationship of PPARs and infectious diseases are reviewed elsewhere [1, 53, 54]. Herein, we focus on the more recently elucidated roles of PPARs in macrophage responses (Figs 1 and 2).

**Bacteria**

As discussed above, PPARγ signaling is important for the development of AMs in the lung as well as promotion of anti-inflammatory macrophages and mitigation of inflammation-induced host damage [25, 26, 28, 33]. In the case of *Streptococcus pneumoniae* infection, PPARγ was critical for dampening the inflammatory response in murine lungs, demonstrating its importance for maintaining lung function and the local lung macrophage population and reducing host mortality [28]. PPARγ is also critical for clearance of methicillin resistant *Staphylococcus aureus* (MRSA) in skin infections. MRSA was able to resist the inflammatory response but succumbs to the resolving abscess microenvironment, which is replete with antimicrobial peptides [55]. Myeloid cell PPARγ signaling was essential for maintaining the resolution phase of MRSA skin infections in mice, and activation of PPARγ hastened the onset of wound resolution [55]. Treatment with the PPARγ agonist pioglitazone in a mouse model of chronic granulomatous disease (CGD; NADPH deficiency) with *S. aureus* infection restored reactive oxygen species (ROS) production by mitochondria in blood monocytes and tissue macrophages [56]. These results were replicated in monocytes from human CGD patients, demonstrating that PPARγ activation appears to bypass the need for NADPH oxidase activation, partially restoring host defense against *S. aureus* in CGD [56]. Activation of PPARγ was also conducive to macrophage killing of *Pseudomonas aeruginosa*, likely through degradation of the bacterium quorum-sensing molecules, which are able to decrease PPARγ expression [57].

In contrast to the activities described above, PPARγ is important for *Mycobacterium tuberculosis* replication [58–60]. Recent studies revealed that macrophages in the lungs of PPARγ knock-out mice, but not peritoneal macrophages or bone marrow derived macrophages (BMDMs), are more resistant to *M. tuberculosis* growth ex vivo [61]. PPARγ deficiency also resulted in increased pro-inflammatory cytokine production in the lungs of *M. tuberculosis*-infected mice, correlating with decreased bacterial burden [61]. Another recent study demonstrated that vitamin B1 can inhibit PPARγ expression, promoting NF-κB signaling and resulting in macrophage control of *M. tuberculosis* [62]. Conversely, PPARα is reported to be essential for antimycobacterial responses by activating autophagy, lipid catabolism, and fatty acid oxidation [52]. Agonists of PPARα promoted autophagy, lysosomal biogenesis, phagosome maturation, and defended against *M. tuberculosis* and *Mycobacterium bovis* bacillus Calmette-Guerin (BCG) in BMDMs [52], demonstrating an important role for PPARα in host defense against mycobacteria.
Less virulent mycobacteria either do not elicit PPARγ expression or induce expression to a lesser extent than virulent strains [58, 63, 64], suggesting that virulent *M. tuberculosis* has evolved to select for induction of PPARγ-mediated pathways in order to alter the environment and enhance its growth. Furthermore, *M. tuberculosis* and *M. bovis* BCG induction of PPARγ signaling is linked to ligation of the pattern recognition receptors (PRRs) mannose receptor (MR; CD206) and toll-like receptor 2 (TLR2), respectively [58, 63, 65]. PPARγ activity in macrophages requires the enzymes cytosolic phospholipase A2 (cPLA2) and 15-lipoxygenase (15-LOX), which are important for the production of inflammatory lipid-signaling molecules, termed eicosanoids, that are linked to both *M. tuberculosis* resistance and susceptibility [58, 66, 67]. Recently, our laboratory has identified several genes regulated by PPARγ during *M. tuberculosis* infection of human macrophages, including cyclooxygenase-2 (COX-2), S100A8, and CMKLR1, which are all linked to eicosanoid production [66]. We also demonstrate that PPARγ induction of the antiapoptotic protein Mcl-1 during *M. tuberculosis* infection inhibits...
Inhibition of Mcl-1 as well as 15-LOX significantly reduced *M. tuberculosis* growth. Altogether, these data indicate that PPARγ is involved in regulating pathways critical for *M. tuberculosis* survival, including apoptosis and the production of lipid mediators. These findings support the idea that *M. tuberculosis* modifies macrophage signaling processes to promote its own survival, which is particularly relevant in AMs.

**Viruses**

M2 macrophages are important for negating damaging inflammation. In a respiratory syncytial virus (RSV) model, PPARγ induced M2 development, decreasing lung pathology [68]. Treatment with the PPARγ agonist rosiglitazone also aided in skewing the macrophages to an M2 phenotype. Patients with human immunodeficiency virus (HIV) infection had decreased PPARγ gene and protein expression in AMs, correlating with increased oxidative stress [69]. Ex vivo treatment with a PPARγ agonist increased PPARγ levels, improved the phagocytic index of the AMs, and decreased oxidative stress [69], thus supporting the potential role of PPARγ agonists for treatment. Monocytes from HIV patients showed reduced expression of not just PPARγ but also PPARα, RXR, PXR, and FXR, which was not restored by highly active antiretroviral therapy (HAART) [70]. Conversely, LXR expression was up-regulated in these patients. This study revealed a correlation between HIV patients’ lipid and cholesterol abnormalities and decreased expression of PPARγ and the cell surface receptor CD36 [70]; the latter aids in uptake of oxidized low-density lipoproteins by monocytes as well as the major surfactant lipid dipalmitoyl phosphatidylcholine [71].

**Sepsis**

Sepsis models have revealed a critical role for PPARγ in controlling inflammation and improving the overall disease outcome. PPARγ gene expression was down-regulated in freshly isolated peripheral blood mononuclear cells (PBMCs) from human sepsis patients [72] as well as in the lungs in a murine sepsis model [73]. In mice, this down-regulation correlated with increased plasma levels of TNF-α, IL-6, and IL-10. Contrary to expectations, peritoneal macrophages from PPARγ knock-out mice released less IL-1α and IL-1β as a result of increased IFN-β in response to lipotoxic stimulation [74]. Treatment with PPARγ agonists improved sepsis outcome, decreasing pro-inflammatory cytokines, increasing IL-10 levels, and improving mouse survival [73, 75]. In a recent study, a PPARγ response element was identified in the microRNA-124 (miR-124) promoter region, and expression of miR-124 was decreased in human sepsis patients and was critical for preventing an exaggerated inflammatory response in septic mice [72]. miR-124 expression was dependent on PPARγ signaling in both human THP-1 macrophage-like cells and RAW264.7 cells [72]. The enzyme PRMT1 was also recently shown to regulate PPARγ’s activity in macrophages in the cecal ligation and puncture sepsis models. Myeloid specific PRMT1 knock-out mice have higher pro-inflammatory cytokine production, defective PPARγ-dependent M2 macrophage activation, and lower survival rates [37]. Rosiglitazone treatment bypassed the IL-4/PRMT1 mechanism to restore PPARγ activity.

Other PPAR isoforms have also been linked to decreased severity of sepsis by down-regulating inflammation. In the cecal ligation and puncture rat sepsis model, treatment with a PPARβ/δ agonist inhibited signal transducer and activator of transcription 3 (STAT3) activation in AMs, reduced the inflammatory response, and prolonged rat survival [76]. However, bacterial counts in the lung were not lowered. Gene expression of the PPARα isoform was down-regulated in whole blood of patients with septic shock [77]. In the mouse model, PPARα signaling was key to amelioration of inflammatory cytokine production during sepsis. Cell surface markers of activation on splenic macrophages were reduced in PPARα-deficient,
septic animals correlating with increased bacterial burden in the lung and splenic tissues [77]. Collectively, these data indicate that PPAR signaling is important for anti-inflammatory macrophage responses during sepsis and suggest that PPAR agonists could alleviate damaging inflammation associated with sepsis, improving disease outcome.

**Fungi and parasites**

Fungi can also induce PPARγ expression and activity in macrophages. PPARγ ligands attenuate *Candida albicans* colonization of the gastrointestinal (GI) tract in mice in a dectin-1 dependent manner [78]. The antimicrobial peptide P17, isolated from ant venom, up-regulates PPARγ expression and activity in human macrophages, leading to increased expression of dectin-1 and MR and less severe *C. albicans* GI infection [79]. A subsequent study identified the NR liver receptor homologue-1 (LRH-1) as important for IL-13-induced PPARγ ligands that are critical for combating GI and systemic *C. albicans* infection [80]. Deficiency in LRH-1 in mice is detrimental to IL-13-mediated M2 macrophage polarization, which is needed to prevent host-damaging inflammation. This study identified a signaling pathway that uses at least two NRs for optimal macrophage responses against *C. albicans*.

PPARγ expression is also regulated by parasite infections [81–84]. During infection with *Plasmodium berghei*, malaria-susceptible mouse strains CBA and C57B6 had higher constitutive PPARγ levels compared to malaria-resistant BALB/c mice; however, in the susceptible mice, PPARγ did not translocate to the nucleus and the mice produced less plasmocidal NO and *H₂O₂* [82].

*Trypanosoma cruzi* infection increased PPARγ expression in murine peritoneal macrophages [83, 84]; however, *T. cruzi* induced PPARα but not PPARγ expression in BMDMs and RAW264.7 macrophages [85]. These data propose a site-specific role for PPAR signaling in macrophages in response to *T. cruzi* infection, similar to that observed for *M. tuberculosis* [61]. Both PPARγ and PPARα agonists induced M2 macrophage activation in peritoneal macrophages infected with *T. cruzi*, increasing phagocytosis of the parasites; however, the anti-parasitic activity of the macrophages was unclear [84, 85]. A new synthetic PPARγ ligand, HP24, decreased inducible nitric oxide synthase (iNOS) expression and stimulated pro-angiogenic mediators in macrophages and in the heart of *T. cruzi*-infected mice, reducing TNF-α and IL-6 release by macrophages [83]. Therefore, induction of PPARγ signaling appears to have a protective role during infection with *T. cruzi*. Administration of PPARγ agonists to *T. cruzi* patients may be a feasible approach to treatment.

PPARγ is also implicated in macrophage responses to schistosomes. Stimulation of peritoneal macrophages and BMDMs with schistosomal-derived lipids or purified lysophosphatidylcholine increased PPARγ expression and induced gene expression of the M2 macrophage hallmarks Arg1, MR, FIZZ1, TGF-β, IL-10, and prostaglandin E2 (PGE2) [86]. During *Schistosoma japonicum* infection in mice, pioglitazone treatment prevented hepatic and splenic pathologies, decreased Th1 T cells and increased regulatory T cells (Tregs) in the liver and spleen [87]. Furthermore, pioglitazone treatment of macrophages promoted Tregs whereas PPARγ inhibitor-treated macrophages reduced the proportion of these cells. The above studies provide evidence that PPARγ signaling is important for antifungal and antiparasitic activity of macrophages by regulating inflammation.

Overall, PPARγ down-regulates pro-inflammatory immune responses during infection, which is vital during the resolution phase to prevent inflammation-induced host damage (Fig 2). Use of PPARγ agonists or antagonists to treat infectious diseases must take into account the timing of administration and the pathogen and must balance pro- and anti-inflammatory
mechanisms to enable an improved outcome. Targeting strategies for other PPARs await further studies.

LXRs

LXRs regulate cholesterol homeostasis and transport and are regulated by oxysterols and intermediate products of cholesterol biosynthetic pathways [88, 89]. LXRs have two isoforms, LXRα (NR1H3) and LXRβ (NR1H2; Table 1), and form obligate heterodimers with RXR [90]. LXRs are also linked to M2 macrophages [91] and could be an attractive target for protection against disease (Fig 2).

Bacteria

LXRs play a role in macrophage survival, preventing bacterial-induced apoptosis during infection with *Listeria monocytogenes*, *Bacillus anthracis*, *Escherichia coli*, and *S. Typhimurium* [92, 93] and contributing to bacterial clearance and resistance to *L. monocytogenes* infection. LXRs have also been linked to macrophage phagocytic responses during *S. Typhimurium* infection. LXR agonists reduced the intracellular levels of NAD in a CD38-dependent manner, counteracting *S. Typhimurium*-induced changes in macrophage morphology and distribution of F-actin in the cytoskeleton [94]. In the mouse model, LXR agonist treatment ameliorated clinical signs of Salmonella infection in a CD38-dependent manner [94].

LXRs are implicated in resistance to *M. tuberculosis* infection [64]. Macrophages infected with *M. tuberculosis* up-regulate LXRα [95] and LXRα deficiency leads to reduced control of intracellular bacterial growth [59, 96]. A build-up of lipid bodies in macrophages is associated with nonprotective responses to *M. tuberculosis*. LXRα activation in THP-1 macrophages increased the expression of the ATP-binding cassette transporters ABCA1 and ABCG1, which are responsible for lipid efflux, resulting in decreased lipid body formation during infection with attenuated *M. tuberculosis* strain H37Rv [95]. Administration of cholesterol-reducing statins has shown promise for tuberculosis (TB) treatment in animal models and clinical trials, which is curiously suggested to occur by reducing LXR activity [97–99]. Further evaluation of LXR activity concurrent with statin administration is required to discern how this intervention affects TB treatment as well as treatment of other infectious diseases, such as *S. aureus* [100], whose clearance can result from statin usage.

Viruses

Up-regulation of the LXR effector ABCA1 is linked to suppression of HIV in humanized mice [101]. Pretreatment of human macrophages with LXR agonist TO901317 reduced the susceptibility of the macrophages to HIV infection, correlating with reduced lipid rafts and up-regulation of ABCA1 expression [102]. Prophylactic and therapeutic administration of the LXR agonist in mice increased resistance to HIV infection and reduced lipidemia [102]. Recent transcriptomic studies investigating susceptibility to dengue virus with a Cuban cohort of African ancestry revealed increased gene expression of RXR in individuals that were more resistant to infection and suggested a protective role for LXR/RXR against dengue virus [103].

LXR signaling was recently implicated in protection against gammaherpes virus MHV68, in which the virus up-regulated LXRα expression in a type-1 interferon dependent manner, which resulted in only moderate to no increase in gene expression for classic LXR target genes ABCA1, FADS2, and SCD2 [104]. Gene expression for ABCA1, FADS2, and SCD2 in macrophages was significantly increased in LXR knock-out mice prior to and after infection with MHV68 [104], leaving the authors to posit that LXR deficiency results in the modulation of LXR corepressor activity, thus increasing transcription of LXR target genes. Macrophages
from LXR deficient mice had increased fatty acid and cholesterol synthesis, two metabolic pathways that support viral replication. Indeed, LXR deficient macrophages permitted increased replication of MHV68. Taken together, these data indicate that LXRs are important for antiviral activities, however the mechanisms of action appear to be distinct for each virus.

**Fungi and parasites**

LXRs are beneficial against bacterial and viral infections [92, 94, 96, 104]. However, mice lacking LXR signaling are more resistant to infection with *Leishmania chagasi* and *Leishmania infantum* [105]. BMDMs from LXRα knock-out mice stimulated with IFN-γ had increased parasite killing ability compared to IFN-γ treated BMDMs from wild-type (WT) mice, producing more nitric oxide (NO) and IL-1β. In addition, LXR ligands abrogated NO production in WT macrophages in response to infection. These data indicate that LXR modulation of host antimicrobial responses is pathogen-specific. Further study is needed to unravel the complex signaling pathways involved.

**LXR regulation of macrophage inflammatory networks**

Numerous mechanistic studies have been undertaken to understand the effects of macrophage LXR activity on inflammatory responses to microbes and their byproducts. Pathogens can interfere with cholesterol metabolism by inhibition of the LXR signaling pathway. For example, microbial ligands initiated interferon regulatory factor 3 (IRF3)-induced TLR3/4, blocking the induction of LXR target genes, including ABCA1, in cultured macrophages [106]. During zymosan-induced acute inflammation, enhanced signaling by the receptor tyrosine kinase Mer increased the activity of LXR, aiding in control of the inflammatory response in macrophages [107].

In multiple macrophage models, LXR activation resulted in down-regulation of LPS-induced inflammatory responses. Both LXRα and LXRβ are expressed in Kupffer cells [108] and required for Kupffer cell development [29]. However, LXRα/β knock-out mice have an increased number of hepatic mononuclear cells with macrophage surface markers that displayed an enhanced inflammatory response to LPS [108]. Pretreatment of Kupffer cells with an LXR agonist prior to LPS administration decreased the amount of pro-inflammatory cytokines produced and increased IL-10 production [109]. This study also suggested that LXRα competes with IRF3 for binding to glucocorticoid receptor-interacting protein 1 (GRIP1), repressing the transcriptional activity of IRF3 and NF-κB, thus inhibiting the LPS-induced inflammatory response. In murine BMDMs, LXRs down-regulate release of pro-inflammatory IL-18 due to LXR’s negative regulation of caspase 1 expression and activation [110]. LXR ligands also induced the expression of IL18BP, a potent IL-18 inhibitor, in an IRF8-dependent manner [110], demonstrating multiple mechanisms at play to limit IL-18 by LXRs.

Taken together, LXR activity generally appears to be an effective method to curb inflammation and induce protective immune responses against infections. However, like other NRs, LXR activity is not protective against all pathogen types. Additional work is needed to discern LXR’s capacity as an HDT for infectious and inflammatory conditions.

**Emerging NR-infectious disease interactions**

**NR4A family**

The NR4A family of nuclear hormone receptors is comprised of three members: Nur77 (NR4A1), Nurrl (NR4A2), and Nor1 (NR4A3; Table 1). No endogenous ligand for these receptors has been identified, resigning the NR4A family to the orphan receptor category.
However, interaction between Nur77’s ligand-binding domain and structurally diverse synthetic molecules have been observed and synthetic ligands have been identified for Nurr1 and Nor1 (reviewed in [111]). NR4As are involved in various cellular processes which are more extensively reviewed elsewhere [111, 112].

All three members of the NR4A family are associated with anti-inflammatory responses because over-expression of these NRs decreased the production of pro-inflammatory cytokines and chemokines, whereas their knock-down resulted in increased cytokine/chemokine synthesis [45]. Nor1, but not the other NR4A NRs, is implicated in the generation of M2 human macrophages in response to IL-4 stimulation; however, gene expression for Nor1 was not increased in IL-4 stimulated murine BMDMs [47]. In contrast, overexpression of Nurr1 in murine BMDMs, but not Nor1 or Nur77, was associated with M2 macrophage development by directly binding to the Arg1 promotor, conferring protection in an LPS-induced sepsis model [49]. LXR agonists induced Nor1 gene expression in murine Kupffer cells, which was important for LXR-mediated dampening of LPS-induced TNF-α production [113]. In an E. coli-induced peritoneal sepsis model, Nur77 did not play a role in host cytokine responses or leukocyte trafficking but was responsible for maintaining vascular impermeability, preventing distant organ damage [114] (Fig 3). Not much is known about NR4A family members for other infectious diseases. However, a recent study showed that murine pulmonary CD11c+ cells up-regulate Nur77 and Nor1 following M. tuberculosis infection with Nor1 being present in PBMCs from human TB patients [115].

Based on limited publications to date, it is apparent that gene expression and activity of NR4A family members vary with species and inflammatory stimuli. However, this family appears to be important for down-regulating inflammatory responses, which could be detrimental to fighting infectious diseases but may also be important for preventing host-damaging inflammation. Further investigation into the NR4A family’s role in macrophage responses to infection is necessary.

**VDR**

The VDR (NR1I1; Table 1) is constitutively expressed in macrophages and has long been studied in conjunction with TB. Polymorphisms in the VDR gene have been associated with increased susceptibility to TB, however inconsistent results have been shown by meta-analysis (reviewed in [64]). Administration of vitamin D along with standard anti-TB drug regimens has improved clinical outcomes in some studies [116]. Addition of vitamin D to THP-1 macrophages down-regulated PPARγ and decreased the number of lipid droplets in M. tuberculosis-infected cells [117], demonstrating a role for the VDR in lipid metabolism during M. tuberculosis infection.

VDR has also been implicated in macrophage responses to parasitic infections. In a Columbian cohort, SNPs in the VDR gene may affect the immune response against T. cruzi [118]. In a mouse model of malaria, infection with Plasmodium chabaudi up-regulated VDR gene expression [119], suggesting that VDR may regulate malaria infection. VDR appears to be nonprotective during Leishmania major infection in mice, with disparity between mouse strains. VDR deficiency in the Th1-predisposed C57B6 mouse resulted in increased resistance to L. major whereas VDR knock-out BALB/c mice, which are Th2-biased, did not reveal a change in susceptibility (Fig 3) [120]. Further study is required to discern the role of VDR during parasitic infections.

**PXR**

The human xenobiotic NR PXR (NR1I2; Table 1) is an adopted orphan NR that is predominantly expressed in the liver and intestines but is also expressed on monocytes and/or
macrophages and lymphocytes [121]. PXR inhibits both innate and adaptive immune responses [122, 123] and are also important for lipid uptake [124]. PXR deficient mice are highly susceptible to *L. monocytogenes* infection, in part due to excessive pro-inflammatory cytokine and chemokine production that resulted in death of inflammatory monocytes [123]. During *M. tuberculosis* infection, PXR promoted foamy macrophage formation and decreased phagolysosomal fusion, inflammatory responses, and apoptosis in human macrophages, enhancing bacterial survival [125].
PXRs regulate various drug metabolizing enzymes and drug transporters that are vital for metabolism, detoxification, and elimination of xenobiotics [126]. Rifampicin, a first line anti-TB drug, is a potent activator of PXRs, which in turn compromises the effect of rifampicin in *M. tuberculosis*-infected human macrophages [127]. Protease inhibitors (PIs) used to treat HIV are associated with dyslipidemia and increased cardiovascular risk and several PIs activate PXRs. Amprenavir, a widely used PI in defense against HIV, is a potent PXR-selective agonist, inducing PXR-targeted CD36 gene expression in mice, resulting in dyslipidemia [128]. Additional studies are warranted to investigate the utility of PXR activity blockade in order to increase drug effectiveness while limiting side effects during treatment of infectious diseases.

**REV-ERBα**

REV-ERBα (NR1D1; Table 1) is a unique NR with an atypical ligand-binding domain that lacks the carboxy-terminal activation function region responsible for transcriptional activation [129]. REV-ERBα is a constitutive transcriptional repressor and competes with other NRs (i.e., PPARγ and LXRs) for response elements, thus altering transcriptional activity [40, 130, 131]. Porphyrin heme was identified as the ligand for REV-ERBα in 2007 [132], changing its categorization to adopted orphan receptor.

The activities of REV-ERBα during infectious disease are mostly unknown, however recent studies with *M. tuberculosis* and LPS challenge have indicated a role for this NR during infection (Fig 3). In human macrophages, REV-ERBα knock-down led to decreased phagolysosomal maturation whereas treatment of THP-1 macrophages with a REV-ERBα agonist increased the number of autophagosomes and lysosomes, correlating with enhanced *M. tuberculosis* clearance [133]. Overexpression of REV-ERBα in human macrophages led to repression of IL-10 and increased phagolysosomal fusion and anti-*M. tuberculosis* activity [41]. This study revealed that a REV-ERBα binding site resides in the promoter region of IL-10 in both humans and nonhuman primates, but not in mice, demonstrating a species disparity [41]. REV-ERBα negatively regulated monocyte chemoattractant protein-1 (MCP-1) and TNF-α secretion in human macrophages stimulated with LPS [40]. REV-ERBα antagonism also suppressed IL-6 and CCL2 gene expression in mice during LPS endotoxin challenge [42, 43], revealing that this NR has both pro- and anti-inflammatory activities. Further investigation into REV-ERBα’s influence on macrophage responses to infection is required.

**Estrogen-related receptors**

ERRs have three isoforms—ERRα (NR3B1), ERRβ (NR2B2), and ERRγ (NR3B3; Table 1)—all of which aid in regulating bioenergetic pathways (reviewed in [134]). ERRα’s up-regulation of mitochondrial ROS contributed to IFN-γ-induced antimicrobial responses to *Listeria* [135]. ERRα has been linked to the activation of autophagy and phagosomal maturation to aid in macrophage defense against *M. tuberculosis* [136]. On the other hand, ERRα acted as a negative regulator of TLR-induced inflammatory responses by inducing *Tnfaip3* transcription [137]. ERRα also negatively regulated macrophage inflammatory responses to endotoxin-induced septic shock through inhibition of NF-kB signaling [137]. Another isoform, ERRγ, may be important for *S. Typhimurium* growth through regulation of hepcidin and host iron homeostasis, because an ERRγ inverse agonist (a molecule that binds to the receptor resulting in activity converse to that of an agonist) reduced intramacrophage proliferation of *S. Typhimurium* [138]. Taken together, these data indicate that ERRs have both protective and nonprotective host properties for pathogens and more study is needed to discern if targeting ERRs would be an effective approach to antimicrobial and/or anti-inflammatory therapy.
FXR

FXR (NR1H4; Table 1) is a metabolic NR that regulates bile acid, lipid, and glucose metabolism (reviewed in [139]) and has recently been linked to sepsis. FXR negatively regulates the NLRP3 inflammasome by physically interacting with NLRP3 and caspase 1, and FXR expression in mice is inversely related to endotoxic shock sensitivity [140]. However, agonism of FXR with GW4064 did not inhibit shock in mice. In another study, this same FXR agonist inhibited NLRP3 inflammasome activation in an FXR-independent manner [141]. These studies highlight that conclusions must be drawn cautiously when interpreting data using only agonists or antagonists, or knock-down or knock-out approaches.

Perspectives and future directions

Considering the pivotal role that NRs play in macrophage responses, in particular their ability to control inflammatory and metabolic pathways, targeting these receptors in macrophages is a promising new HDT approach for infectious diseases. The NRs PPARγ and LXR have been most studied in regard to bacterial, viral, fungal, and parasitic infections; however, the importance of other NRs, including the NR4A family, PXR, and REV-ERBα is beginning to emerge (Fig 3). Given that 48 NRs have been identified to date in humans [6], it is likely that additional NRs will be identified to regulate macrophage responses to infection.

There are existing pharmacological interventions that target NRs, supporting their feasibility for use in combatting infectious diseases. However, it is clear that NRs modulate metabolism and inflammation in a tissue-, gene- and signal-specific manner. Furthermore, as highlighted in this review, certain NRs mediate either resistance or susceptibility to infection, depending on the microbe in question. Therefore, care must be taken when targeting specific NRs as a treatment for infectious diseases.

The next steps in the NR field require both a basic science and translational approach. It is critical that we identify the steps that occur upstream of NR activation. Cross-talk between NRs as well as between NRs and the signaling pathways of PRRs including TLRs, nucleotide oligomerization domain (NOD)-like receptors (NLRs), and C-type lectin receptors (CLRs) must be defined to discern the mechanisms behind NR activation. Further understanding regarding ligands (endogenous and synthetic) for NRs and NR effectors is also required. In addition, it is imperative to consider the translatability between in vitro and in vivo systems as well as potential species disparities. Further research into these topics will be key for identification of NRs that can be used to treat infectious diseases in humans.

Some NR agonists and antagonists lack specificity for their intended target, resulting in off-target effects that can have undesirable or unacceptable side effects [142–144]. Therefore, future NR-targeted interventions will need to be more specific and studied carefully in different infectious disease models. For example, many NRs are involved in the inflammatory response during infection, making NRs attractive targets to limit tissue-damaging inflammation. However, the timing of administration will need to be investigated further so as to not hinder the natural host antimicrobial response. Furthermore, the broad and diverse roles of NRs including regulation of basic processes like circadian rhythm and cholesterol transport or their roles in other diseases such as autoimmunity, obesity, and atherosclerosis must be taken into account when using NR modulators to treat infections.

We must also be cautious when drawing conclusions based on agonist–antagonist data. Both agonists and antagonists should be used and knock-down and/or knock-out models, when available, should also be used to confirm that the effects observed with agonists–antagonists are specific and not due to off-target effects. Similarly, concentration and timing of
agonist–antagonist administration should be carefully planned to reduce likelihood of undetected off-target effects.

In conclusion, there is a need to continue to study NR mechanisms of action in well-defined model systems in order to develop new chemical classes of ligands and inhibitors with the ability to selectively modulate NR function. This selectivity of novel HDTs must be achieved if this line of treatment is to be feasible. In this era of increasing antimicrobial resistance, future study identifying and characterizing NRs during infections is not only warranted but compulsory if we are to consider new HDT approaches that augment antimicrobials in combating these deadly diseases.

Acknowledgments

The authors would like to thank Christopher D. Wager, Jr., for assistance with the illustrations for this review.

References

1. Mahajan S, Saini A, Kalra R, Gupta P. Frienemies of infection: A chronic case of host nuclear receptors acting as cohorts or combatants of infection. Critical reviews in microbiology. 2016; 42(4):526–34. https://doi.org/10.3109/1040841X.2014.970122 PMID: 25395058.

2. Chawla A. Control of macrophage activation and function by PPARs. Circ Res. 2010; 106(10):1559–69. https://doi.org/10.1161/CIRCRESAHA.110.216523 PMID: 20508200; PubMed Central PMCID: PMCPMC2897247.

3. Nagy L, Szanto A, Szatmari I, Széles L. Nuclear hormone receptors enable macrophages and dendritic cells to sense their lipid environment and shape their immune response. Physiol Rev. 2012; 92(2):739–89. https://doi.org/10.1152/physrev.00004.2011 PMID: 22835896.

4. Glass CK, Saljo K. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nature reviews Immunology. 2010; 10(5):365–76. https://doi.org/10.1038/nri2748 PMID: 20414208.

5. Kiss M, Czimmerer Z, Nagy L. The role of lipid-activated nuclear receptors in shaping macrophage and dendritic cell function: From physiology to pathology. J Allergy Clin Immunol. 2013; 132(2):264–86. https://doi.org/10.1016/j.jaci.2013.05.044 PMID: 23905916.

6. Maglich JM, Sluder A, Guan X, Shi Y, McKee DD, Carrick K, et al. Comparison of complete nuclear receptor sets from the human, Caenorhabditis elegans and Drosophila genomes. Genome Biol. 2001; 2(8):RESEARCH0029. PMID: 11532213; PubMed Central PMCID: PMCPMC5532.

7. Barish GD, Downes M, Alaynick WA, Yu RT, Ocampo CB, Bookout AL, et al. A Nuclear Receptor Atlas: macrophage activation. Mol Endocrinol. 2005; 19(10):2466–77. Epub 2005/07/30. https://doi.org/10.1210/me.2004-0529 PMID: 16051664.

8. Glass CK, Ogawa S. Combinatorial roles of nuclear receptors in inflammation and immunity. Nature reviews Immunology. 2006; 6(1):44–55. Epub 2006/02/24. https://doi.org/10.1038/nri1748 PMID: 16493426.

9. Cox C. How much does the U.S. spend to treat different diseases? Peterson-Kaiser Health System Tracker. 2017. Epub May 22, 2017.

10. Via M. Nuclear Receptors: The Pipeline Outlook. Insight Pharma Reports. 2010.

11. Huang P, Chandra V, Rastinejad F. Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics. Annual review of physiology. 2010; 72:247–72. https://doi.org/10.1146/annurev-physiol-021909-135917 PMID: 20148675; PubMed Central PMCID: PMCPMC3677810.

12. Perissi V, Aggarwal A, Glass CK, Rose DW, Rosenfeld MG. A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors. Cell. 2004; 116(4):511–26. Epub 2004/02/26. PMID: 14980219.

13. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, et al. PPAR gamma signaling and metabolism: the good, the bad and the future. Nat Med. 2013; 19(5):557–66. https://doi.org/10.1038/nm.3159 PMID: 23652116; PubMed Central PMCID: PMCPMC3870016.

14. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000prime reports. 2014; 6:13. https://doi.org/10.12703/P6-13 PMID: 24669294; PubMed Central PMCID: PMCPMC3944739.
15. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annual review of immunology. 2009; 27:451–83. Epub 2008/12/25. https://doi.org/10.1146/annurev.immunol.021908.132532 PMID: 19105661.

16. Leopold Wager CM, Wormley FL. Classical versus alternative macrophage activation: the Ying and the Yang in host defense against pulmonary fungal infections. Mucosal Immunol. 2014; 7(5):1023–35. https://doi.org/10.1038/mi.2014.65 PubMed Central PMCID: PMCPMC Journal—In Process. PMID: 25073676

17. Guirado E, Schlesinger LS, Kaplan G. Macrophages in tuberculosis: friend or foe. Seminars in Immunopathology. 2013; 35(5):563–83. https://doi.org/10.1007/s00281-013-0388-2 WOS:000323108500004. PMID: 23864058

18. Rajaram MV, Ni B, Dodd CE, Schlesinger LS. Macrophage immunoregulatory pathways in tuberculosis. Seminars in immunology. 2014; 26(6):471–85. https://doi.org/10.1016/j.smim.2014.09.010 PMID: 25453226; PubMed Central PMCID: PMCPMC4314327.

19. Torrelles JB, Schlesinger LS. Integrating Lung Physiology, Immunology, and Tuberculosis. Trends Microbiol. 2017; 25(8):688–97. https://doi.org/10.1016/j.tim.2017.03.007 PMID: 28366292; PubMed Central PMCID: PMCPMC5522344.

20. Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, Quester I, et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity. 2014; 40(2):274–88. Epub 2014/02/18. https://doi.org/10.1016/j.immuni.2014.01.006 PMID: 24530056; PubMed Central PMCID: PMCPMC3991396.

21. Sudan B, Wacker MA, Wilson ME, Graff JW. A Systematic Approach to Identify Markers of Distinctly Activated Human Macrophages. Front Immunol. 2015; 6:253. Epub 2015/06/16. https://doi.org/10.3389/fimmu.2015.00253 PMID: 26074920; PubMed Central PMCID: PMCPMC4445890.

22. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014; 41(1):14–20. Epub 2014/07/19. https://doi.org/10.1016/j.immuni.2014.06.008 PMID: 25035950; PubMed Central PMCID: PMCPMC4123412.

23. Edwards JP, Zhang X, Frauwirth KA, Mosser DM. Biochemical and functional characterization of three activated macrophage populations. J Leukoc Biol. 2006; 80(6):1298–307. Epub 2006/08/15. https://doi.org/10.1189/jlb.0406249 PMID: 16905575; PubMed Central PMCID: PMCPMC2642590.

24. Gundra UM, Girgis NM, Ruckerl D, Jenkins S, Ward LN, Kurtz ZD, et al. Alternatively activated macrophages derived from monocytes and tissue macrophages are phenotypically and functionally distinct. Blood. 2014; 123(20):e110–22. Epub 2014/04/04. https://doi.org/10.1182/blood-2013-08-520619 PMID: 24695852; PubMed Central PMCID: PMCPMC4023427.

25. Todd EM, Zhou JY, Szasz TP, Deady LE, D’Angelo JA, Cheung MD, et al. Alveolar macrophage development in mice requires L-plastin for cellular localization in alveoli. Blood. 2016; 128(24):2785–96. https://doi.org/10.1182/blood-2016-03-705962 PMID: 27758872; PubMed Central PMCID: PMCPMC5159703.

26. Schneider C, Nobs SP, Kurrer M, Rehrauer H, Thiele C, Kopf M. Induction of the nuclear receptor PPAR-gamma by the cytokine GM-CSF is critical for the differentiation of fetal monocytes into alveolar macrophages. Nature immunology. 2014; 15(11):1026–37. https://doi.org/10.1038/ni.3005 PMID: 25263125.

27. Yu X, Buttgereit A, Lelios I, Utz SG, Cansever D, Becher B, et al. The Cytokine TGF-beta Promotes the Development and Homeostasis of Alveolar Macrophages. Immunity. 2017; 47(5):903–12 e4. https://doi.org/10.1016/j.immuni.2017.10.007 PMID: 29126797.

28. Gautier EL, Chow A, Spanbroek R, Marcelin G, Greter M, Jakubzick C, et al. Systemic analysis of PPAR gamma in mouse macrophage populations reveals marked diversity in expression with critical roles in resolution of inflammation and airway immunity. Journal of immunology. 2012; 189(5):2614–24. https://doi.org/10.4049/jimmunol.1200495 PMID: 22855714; PubMed Central PMCID: PMCPMC3537497.

29. Scott CL, T’Jonck W, Martens L, Todorov H, Sichern D, Soen B, et al. The Transcription Factor ZEB2 Is Required to Maintain the Tissue-Specific Identities of Macrophages. Immunity. 2018; 49(2):312–25 e5. https://doi.org/10.1016/j.immuni.2018.07.004 PMID: 30076102; PubMed Central PMCID: PMCPMC6104815.

30. N AG, Guillen JA, Gallardo G, Diaz M, de la Rosa JV, Hernandez IH, et al. The nuclear receptor LXRalpha controls the functional specialization of splenic macrophages. Nature immunology. 2013; 14 (8):831–9. https://doi.org/10.1038/ni.2622 PMID: 23770640; PubMed Central PMCID: PMCPMC3720666.

31. Bonfield TL, Farver CF, Barna BP, Malur A, Abraham S, Raychaudhuri B, et al. Peroxisome proliferator-activated receptor-gamma is deficient in alveolar macrophages from patients with alveolar...
32. Asada K, Sasaki S, Suda T, Chida K, Nakamura H. Antiinflammatory roles of peroxisome proliferator-activated receptor gamma in human alveolar macrophages. American Journal of Respiratory and Critical Care Medicine. 2004; 169(2):195–200. Epub 2003/10/18. https://doi.org/10.1164/rccm.2003-0148OC PMID: 14563653.

33. Malur A, McCoy AJ, Arce S, Barma BP, Kavuru MS, Malur AG, et al. Deletion of PPAR gamma in alveolar macrophages is associated with a Th-1 pulmonary inflammatory response. Journal of Immunology. 2009; 182(9):5816–22. https://doi.org/10.4049/jimmunol.0803504 PMID: 19380830.

34. Guo B, Huang X, Lee MR, Lee SA, Broxmeyer HE. Antagonism of PPAR-gamma signaling expands human hematopoietic stem and progenitor cells by enhancing glycolysis. Nat Med. 2018; 24(3):360–7. Epub 2018/01/30. https://doi.org/10.1038/nm.4477 PMID: 29377004; PubMed Central PMCID: PMCPMC5875416.

35. Tikhanovich I, Zhao J, Olson J, Adams A, Taylor R, Bridges B, et al. Protein arginine methyltransferase 1 modulates innate immune responses through regulation of peroxisome proliferator-activated receptor gamma-dependent macrophage differentiation. J Biol Chem. 2017; 292(17):6882–94. Epub 2017/03/24. https://doi.org/10.1074/jbc.M117.778761 PMID: 28330886; PubMed Central PMCID: PMCPMC494549.

36. Fontaine C, Rigamonti E, Pourcet B, Duez H, Duhem C, Fruchart JC, et al. The nuclear receptor Rev-erbalpha is a liver X receptor (LXR) target gene driving a negative feedback loop on select LXR-induced pathways in human macrophages. Mol Endocrinol. 2008; 22(8):1797–811. https://doi.org/10.1210/me.2007-0439 PMID: 18511497; PubMed Central PMCID: PMCPMC5419447.

37. Sato S, Sakurai T, Ogasawara J, Shirato K, Ishibashi Y, Ohishi S, et al. Direct and indirect suppression of interleukin-6 gene expression in murine macrophages by nuclear orphan receptor REV-ERBalpha. Scientific World Journal. 2014; 2014:685854. https://doi.org/10.1155/2014/685854 PMID: 25401152; PubMed Central PMCID: PMCPMC4220616.

38. Sato S, Sakurai T, Ogawara J, Shirato K, Ishibashi Y, Ohishi S, et al. A circadian clock gene, Rev-erbalpha, modulates the inflammatory function of macrophages through the negative regulation of Ccl2 expression. Journal of Immunology. 2014; 192(1):407–17. Epub 2013/12/07. https://doi.org/10.4049/jimmunol.1301982 PMID: 24307731.

39. Pei L, Castrillo A, Chen M, Hoffmann A, Tontonoz P. Induction of NR4A orphan nuclear receptor expression in macrophages in response to inflammatory stimuli. J Biol Chem. 2005; 280(32):29256–62. https://doi.org/10.1074/jbc.M502606200 PMID: 15964844.

40. Bonta PI, van Tiel CM, Vos M, Pols TW, van Thienen JV, Ferreira V, et al. Nuclear receptors Nur77, Nur1, and NOR-1 expressed in atherosclerotic lesion macrophages reduce lipid loading and inflammatory responses. Arterioscler Thromb Vasc Biol. 2006; 26(10):2288–94. https://doi.org/10.1161/01.ATV.0000238346.84438.5d PMID: 16873729.

41. De Paoli F, Eeckhoute J, Copin V, Vanhoutte J, Duhem C, Derudas B, et al. The neuron-derived orphan receptor 1 (NOR1) is induced upon human alternative macrophage polarization and stimulates
the expression of markers of the M2 phenotype. Atherosclerosis. 2015; 241(1):18–26. https://doi.org/10.1016/j.atherosclerosis.2015.04.798 PMID: 25941992.

48. Kurakula K, Vos M, Logiantara A, Roelofs JJ, Nieuwenhuis MA, Koppelman GH, et al. Nuclear Receptor Nur77 Attenuates Airway Inflammation in Mice by Suppressing NF-kappaB Activity in Lung Epithelial Cells. Journal of Immunology. 2015; 195(4):1388–98. https://doi.org/10.4049/jimmunol.1401714 PMID: 26170382.

49. Mahajan S, Saini A, Chandra V, Nanduri R, Kalra R, Bhagya raj E, et al. Nuclear Receptor Nr4a2 Promotes Alternative Polarization of Macrophages and Confers Protection in Sepsis. J Biol Chem. 2015; 290(30):18304–14. https://doi.org/10.1074/jbc.M115.638064 PMID: 25953901; PubMed Central PMCID: PMCPMC4513091.

50. Mc Morrow JP, Murphy EP. Inflammation: a role for NR4A orphan nuclear receptors? Biochem Soc Trans. 2011; 39(2):688–93. https://doi.org/10.1042/BST0390688 PMID: 21428963.

51. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998; 391(6662):82–6. https://doi.org/10.1038/34184 PMID: 9425209.

52. Kim YS, Lee HM, Kim JK, Yang CS, Kim TS, Jung M, et al. PPAR- alpha Activation Mediates Innate Host Defense through Induction of TFEB and Lipid Catabolism. Journal of immunology. 2017; 198(8):3283–95. https://doi.org/10.4049/jimmunol.1601920 PMID: 28275133.

53. Almeida PE, Carneiro AB, Silva AR, Bozza PT. PPAR gamma Expression and Function in Mycobacteria Infection: Roles in Lipid Metabolism, Immunity, and Bacterial Killing. PPAR Res. 2012; 2012:383829. https://doi.org/10.1155/2012/383829 PMID: 22851964; PubMed Central PMCID: PMCPMC3407650.

54. Reddy AT, Lakshmi SP, Reddy RC. PPARgamma in Bacterial Infections: A Friend or Foe? PPAR Res. 2016; 2016:7963540. Epub 2016/10/25. https://doi.org/10.1155/2016/7963540 PMID: 27774097; PubMed Central PMCID: PMCPMC5059608.

55. Thurlow LR, Joshi GS, Richardson AR. Peroxisome Proliferator-Activated Receptor gamma Is Essential for the Resolution of Staphylococcus aureus Skin Infections. Cell host & microbe. 2018; 24(2):261–70 e4. Epub 2018/07/31. https://doi.org/10.1016/j.chom.2018.07.001 PMID: 30057172.

56. Fernandez-Boyanapalli RF, Frasch SC, Thomas SM, Malcolm KC, Nicks M, Harbeck RJ, et al. Pioglitazone restores phagocyte mitochondrial oxidants and bactericidal capacity in chronic granulomatous disease. J Allergy Clin Immunol. 2015; 135(2):517–27 e12. Epub 2014/12/17. https://doi.org/10.1016/j.jaci.2014.09.034 PMID: 25488313; PubMed Central PMCID: PMCPMC4331116.

57. Bedi B, Yuan Z, Joo M, Zughair SM, Goldberg JB, Arbiser JL, et al. Enhanced Clearance of Pseudomonas aeruginosa by Peroxisome Proliferator-Activated Receptor Gamma. Infect Immun. 2016; 84(7):1975–85. Epub 2016/04/20. https://doi.org/10.1128/IAI.00164-16 PMID: 27091928; PubMed Central PMCID: PMCPMC4936346.

58. Rajaram MV, Brooks MN, Morris JD, Torrelles JB, Azad AK, Schlesinger LS. Mycobacterium tuberculosis activates human macrophage peroxisome proliferator-activated receptor gamma linking manganese receptor recognition to regulation of immune responses. Journal of immunology. 2010; 185(2):929–42. https://doi.org/10.4049/jimmunol.1000866 PMID: 20554962; PubMed Central PMCID: PMCPMC3014549.

59. Mahajan S, Dkhar HK, Chandra V, Dave S, Nanduri R, Janmeja AK, et al. Mycobacterium tuberculosis modulates macrophage lipid-sensing nuclear receptors PPAR gamma and TR4 for survival. Journal of immunology. 2012; 188(11):5593–603. https://doi.org/10.4049/jimmunol.1103038 PMID: 22544925.

60. Rothchild AC, Stowell B, Goyal G, Nunes-Alves C, Yang Q, Papavinasasundaram K, et al. Role of Granulocyte-Macrophage Colony-Stimulating Factor Production by T Cells during Mycobacterium tuberculosis Infection. MBio. 2017; 8(5). doi: 10.1128/mBio.01514-17 PubMed PMID: 29065647; PubMed Central PMCID: PMCPMC5654932.

61. Guirado E, Rajaram MV, Chawla A, Daigle J, La Perle KMD, Arnett E, et al. Deletion of PPAR-gamma in lung macrophages provides an immunoprotective response against M. tuberculosis infection in mice. Tuberculosis (Edinb). 2018. https://doi.org/10.1016/j.tube.2018.06.012 PMID: 30029904.

62. Hu S, He W, Du X, Huang Y, Fu Y, Yang Y, et al. Vitamin B1 Helps to Limit Mycobacterium tuberculosis Growth via Regulating Innate Immunity in a Peroxisome Proliferator-Activated Receptor-gamma-Dependent Manner. Front Immunol. 2018; 9:1778. https://doi.org/10.3389/fimmu.2018.01777 PMID: 30166982; PubMed Central PMCID: PMCPMC6106772.

63. Almeida PE, Silva AR, Maya-Monteiro CM, Torocosik D, D’Avila H, Dezso B, et al. Mycobacterium bovis bacillus Calmette-Guerin infection induces TLR2-dependent peroxisome proliferator-activated receptor gamma expression and activation: functions in inflammation, lipid metabolism, and pathogenesis. Journal of immunology. 2009; 183(2):1337–45. https://doi.org/10.4049/jimmunol.0900365 PMID: 19561094.
Renga B, Francisc i D, D'Amore C, Schiaroli E, Carino A, Baldelli F, et al. HIV-1 infection is associated with changes in nuclear receptor transcriptome, pro-inflammatory and lipid profile of monocytes. BMC infectious diseases. 2012; 12:274. Epub 2012/10/31. https://doi.org/10.1186/1471-2334-12-274 PMID: 23106848; PubMed Central PMCID: PMCPM3528633.

Shirley KA, Lai W, Pletneva LM, Finkelman FD, Feola DJ, Bianco JC, et al. Agents that increase AAM differentiation blunt RSV-mediated lung pathology. J Leukoc Biol. 2014; 96(6):951–5. https://doi.org/10.1189/jlb.4H I0414-226R PMID: 25009233; PubMed Central PMCID: PMCPM4226793.

Yeligar SM, Ward JM, Harris FL, Brown LAS, Guidot DM, Cribbs SK. Dysregulation of Alveolar Macrophage Surface CD36-Mediated Uptake of Surfactant Lipids by Human Macrophages Promotes Intracellular Growth of Mycobacterium tuberculosis. Journal of immunology. 2016; 197(12):4727–35. Epub 2016/12/04. https://doi.org/10.4049/jimmunol.1600856 PMID: 27913648; PubMed Central PMCID: PMCPM137903.

Wang D, Shi L, Xin W, Xu J, Xu J, Li Q, et al. Activation of PPARgamma inhibits pro-inflammatory and antifungal phenotypes of IL-13-activated macrophages through the PPARgamma ligand ciglitazone. Biochem Biophys Res Commun. 2017; 486(3):726–31. Epub 2017/03/28. https://doi.org/10.1016/j.bbrc.2017.03.106 PMID: 28342874.

Zingarelli B, Sheehan M, Hake PW, O'Connor M, Denenberg A, Cook JA. Peroxisome proliferator activator receptor-gamma ligands, 15-deoxy-Delta(12,14)-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways. Journal of immunology. 2003; 171(12):6827–37. Epub 2003/12/10. PMID: 14662889.

Weber KJ, Sauer M, He L, Tycksen E, Kalugotla G, Razani B, et al. PPARgamma Deficiency Suppresses the Release of IL-1beta and IL-1alpha in Macrophages via a Type 1 IFN-Dependent Mechanism. Journal of immunology. 2018; 201(7):2054–69. Epub 2018/08/26. https://doi.org/10.4049/jimmunol.1800224 PMID: 30143592; PubMed Central PMCID: PMCPM6147147.

Ferreira AE, Sisti F, Sonego F, Wang S, Filgueiras LR, Brandt S, et al. PPAR-gamma/IL-10 axis inhibits MyD88 expression and ameliorates murine polymicrobial sepsis. Journal of immunology. 2014; 192(5):2357–65. Epub 2014/02/04. https://doi.org/10.4049/jimmunol.1302375 PMID: 24489087; PubMed Central PMCID: PMCPM3943997.

Wang C, Zhou G, Zeng Z. Effects of peroxisome proliferator-activated receptor-beta/delta on sepsis induced acute lung injury. Chin Med J (Engl). 2014; 127(11):2129–37. PMID: 24890166.

Standage SW, Caldwell CC, Zingarelli B, Wong HR. Reduced peroxisome proliferator-activated receptor alpha expression is associated with decreased survival and increased tissue bacterial load in sepsis. Shock. 2012; 37(2):164–9. Epub 2011/11/18. https://doi.org/10.1097/SHK.0b013e31823f1a00 PMID: 22089192; PubMed Central PMCID: PMCPM3261332.

Gales A, Conduche A, Bernad J, Lefevre L, Olagnier D, Beraud M, et al. PPARgamma controls DCs-1 expression required for host antifungal defense against Candida albicans. PLoS Pathog. 2010; 6 (1):e1000714. Epub 2010/01/12. https://doi.org/10.1371/journal.ppat.1000714 PMID: 20062524; PubMed Central PMCID: PMCPM2795865.

Bennoussaa K, Authier H, Prat M, AlaEddine M, Lefevre L, Rahabi MC, et al. P17, an Original Host Defense Peptide from Ant Venom, Promotes Antifungal Activities of Macrophages through the Induction of C-Type Lectin Receptors Dependent on LTB4-Mediated PPARgamma Activation. Front Immunol. 2017; 8:1650. https://doi.org/10.3389/fimmu.2017.01650 PMID: 29250064; PubMed Central PMCID: PMCPM5716351.

Lefevre L, Authier H, Stein S, Majorel C, Couderc B, Dardenne C, et al. LRH-1 mediates anti-inflammatory and antifungal phenotype of IL-13-activated macrophages through the PPARgamma ligand.
81. He X, Gong P, Wei Z, Liu W, Wang W, Li J, et al. Peroxisome proliferator-activated receptor-gamma-mediated polarization of macrophages in Neospora caninum infection. Exp Parasitol. 2017; 178:37–44. Epub 2017/05/22. https://doi.org/10.1016/j.exppara.2017.05.002 PMID: 28527905.

82. Borges TK, Alves EA, Vasconcelos HA, Carneiro FP, Nicola AM, Magalhaes KG, et al. Differences in the modulation of reactive species, lipid bodies, cyclooxygenase-2, 5-lipoxygenase and PPAR-gamma in cerebral malaria-susceptible and resistant mice. Immunobiology. 2017; 222(4):604–19. Epub 2016/11/27. https://doi.org/10.1016/j.imbio.2016.11.010 PMID: 27887739.

83. Penas FN, Carta D, Dmytrenko G, Mirkin GA, Modenutti CP, Cevey AC, et al. Treatment with a New Peroxisome Proliferator-Activated Receptor Gamma Agonist, Pyridinecarboxylic Acid Derivative, Increases Angiogenesis and Reduces Inflammatory Mediators in the Heart of Trypanosoma cruzi-Infected Mice. Front Immunol. 2017; 8:1738. Epub 2018/01/10. https://doi.org/10.3389/fimmu.2017.01738 PMID: 29312293; PubMed Central PMCID: PMCPMC5732351.

84. Penas F, Mirkin GA, Vera M, Cevey A, Gonzalez CD, Gomez MI, et al. Treatment in vitro with PPARalpha and PPARgamma ligands drives M1-to-M2 polarization of macrophages from T. cruzi-infected mice. Biochim Biophys Acta. 2015; 1852(5):893–904. https://doi.org/10.1016/j.bbadis.2014.12.019 PMID: 25557389.

85. Koo SJ, Szczesny B, Wan X, Putluri N, Garg NJ. Pentose Phosphate Shunt Modulates Reactive Oxygen Species and Nitric Oxide Production Controlling Trypanosoma cruzi in Macrophages. Front Immunol. 2018; 9:202. Epub 2018/03/06. https://doi.org/10.3389/fimmu.2018.00202 PMID: 29503646; PubMed Central PMCID: PMCPMC5732351.

86. Han S, Zhuang H, Shumyak S, Wu J, Xie C, Li H, et al. Liver X Receptor Agonist Therapy Prevents Diffuse Alveolar Hemorrhage in Murine Lupus by Repolarizing Macrophages. Cell. 2004; 119(2):299–309. https://doi.org/10.1016/j.cell.2004.09.032 PMID: 15479645.

87. Valledor AF, Hsu LC, Ogawa S, Sawka-Verhelle D, Karin M, Glass CK. Activation of liver X receptors prevents bacterial-induced macrophage apoptosis. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101(51):17813–8. https://doi.org/10.1073/pnas.0407749101 PMID: 15601766; PubMed Central PMCID: PMCPMC397595.

88. Matalonga J, Giara E, Bresque M, Escande C, Carbo JM, Kiefer K, et al. The Nuclear Receptor LXR Limits Bacterial Infection of Host Macrophages through a Mechanism that Impacts Cellular NAD Metabolism. Cell Rep. 2017; 18(5):1241–55. Epub 2017/02/02. https://doi.org/10.1016/j.celrep.2017.01.007 PMID: 28147278.

89. Bottlier M, Lapierre D, Memari B, Mangiapane J, Fiore A, Mitchell E, et al. Alu repeats as transcriptional regulatory platforms in macrophage responses to M. tuberculosis infection. Nucleic acids research. 2016; 44(22):10571–67. https://doi.org/10.1093/nar/gkw782 PMID: 27604870; PubMed Central PMCID: PMCPMC5159939.
96. Korf H, Vander Beken S, Romano M, Steffensen KR, Stijlemans B, Gustafsson JA, et al. Liver X receptors contribute to the protective immune response against Mycobacterium tuberculosis in mice. J Clin Invest. 2009; 119(6):1626–37. https://doi.org/10.1172/JCI35288 PMID: 19436111; PubMed Central PMCID: PMCPMC2689129.

97. Bah SY, Dickinson P, Forster T, Kampmann B, Ghazal P. Immune oxysterols: Role in mycobacterial infection and inflammation. J Steroid Biochem Mol Biol. 2017; 169:152–63. https://doi.org/10.1016/j.jsbmb.2016.04.015 PMID: 27155346.

98. Su YY, Su WJ, Yen YF, Pan SW, Chuang PH, Feng JY, et al. Statin Use Is Associated With a Lower Risk of TB. Chest. 2017; 152(3):598–606. https://doi.org/10.1016/j.chest.2017.04.170 PMID: 28479115.

99. Dutta NK, Bruiners N, Pinn ML, Zimmerman MD, Prideaux B, Dartois V, et al. Statin adjunctive therapy shortens the duration of TB treatment in mice. J Antimicrob Chemother. 2016; 71(6):1570–7. https://doi.org/10.1093/jac/dkw014 PMID: 26903278; PubMed Central PMCID: PMCPMC5007636.

100. Smit J, Lopez-Cortes LE, Thomsen RW, Schonheyder HC, Nielsen H, Froslev T, et al. Statin Use and Risk of Community-Acquired Staphylococcus aureus Bacteremia: A Population-Based Case-Control Study. Mayo Clin Proc. 2017; 92(10):1469–78. Epub 2017/10/07. https://doi.org/10.1016/j.mayocp.2017.07.008 PMID: 28982483.

101. Mujawar Z, Rose H, Morrow MP, Pushkarsky T, Dubrovsky L, Mukhamedova N, et al. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol. 2006; 4(11):e365. Epub 2006/11/02. https://doi.org/10.1371/journal.pbio.0040365 PMID: 17076584; PubMed Central PMCID: PMCPMC1629034.

102. Ramezani A, Dubrovsky L, Pushkarsky T, Sviridov D, Karandish S, Raj DS, et al. Stimulation of Liver X Receptor Has Potent Anti-HIV Effects in a Humanized Mouse Model of HIV Infection. J Pharmacol Exp Ther. 2015; 354(3):376–83. Epub 2015/07/02. https://doi.org/10.1124/jpet.115.224485 PMID: 26126533; PubMed Central PMCID: PMCPMC4538872.

103. Sierra B, Triska P, Soares P, Garcia G, Perez AB, Aguirre E, et al. OSBPL10, RXRA and lipid metabolism confer African-ancestry protection against dengue haemorrhagic fever in admixed Cubans. PLoS Pathog. 2017; 13(2):e1006220. Epub 2017/02/28. https://doi.org/10.1371/journal.ppat.1006220 PMID: 28241052; PubMed Central PMCID: PMCPMC5344536.

104. Lange PT, Schorl C, Sahoo D, Tarakanova VL. Liver X Receptors Suppress Activity of Cholesterol and Fatty Acid Synthesis Pathways To Oppose Gammaherpesvirus Replication. MBio. 2018; 9(4). Epub 2018/07/19. https://doi.org/10.1128/mBio.01115-18 PMID: 30018108; PubMed Central PMCID: PMCPMC6050960.

105. Bruhn KW, Marathe C, Maretti-Mira AC, Nguyen H, Haskell J, Tran TA, et al. LXR deficiency confers increased protection against visceral Leishmania infection in mice. PLoS Negl Trop Dis. 2010; 4(11):e886. Epub 2010/11/26. https://doi.org/10.1371/journal.pntd.0000886 PMID: 21103366; PubMed Central PMCID: PMCPMC2982826.

106. Castrillo A, Joseph SB, Vaidya SA, Haberland M, Fogelman AM, Cheng G, et al. Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol Cell. 2003; 12(4):805–16. Epub 2003/10/29. PMID: 14580335.

107. Choi JY, Seo JY, Yoon YS, Lee YJ, Kim HS, Kang JL. Mer signaling increases the abundance of the transcription factor LXR to promote the resolution of acute sterile inflammation. Science signaling. 2015; 8(365):ra21. Epub 2015/02/26. https://doi.org/10.1126/scisignal.2005864 PMID: 25714463.

108. Endo-Umeda K, Nakashima H, Komine-Aizawa S, Umeda N, Seki S, Makishima M. Liver X receptors regulate hepatic F4/80 (+) CD11b(+) Kupffer cells/macrophages and innate immune responses in mice. Scientific reports. 2018; 8(1):9281. Epub 2018/06/20. https://doi.org/10.1038/s41598-018-27615-7 PMID: 29915246; PubMed Central PMCID: PMCPMC6006359.

109. Miao CM, He K, Li PZ, Liu ZJ, Zhu XW, Ou ZB, et al. LXRalpha represses LPS-induced inflammatory responses by competing with IRF3 for GRIP1 in Kupffer cells. Int Immunopharmacol. 2016; 35:272–9. Epub 2016/04/18. https://doi.org/10.1016/j.intimp.2016.04.009 PMID: 27085678.

110. Pourcet B, Gage MC, Leon TE, Waddington KE, Pello OM, Steffensen KR, et al. The nuclear receptor LXR modulates interleukin-18 levels in macrophages through multiple mechanisms. Scientific reports. 2016; 6:25481. Epub 2016/05/07. https://doi.org/10.1038/srep25481 PMID: 27149934; PubMed Central PMCID: PMCPMC4858669.

111. Safe S, Jin UH, Morpurgo B, Abdayye A, Singh M, Tjalkens RB. Nuclear receptor 4A (NR4A) family—orphans no more. J Steroid Biochem Mol Biol. 2016; 157:48–60. Epub 2015/04/29. https://doi.org/10.1016/j.jsbmb.2015.04.016 PMID: 25917081; PubMed Central PMCID: PMCPMC4618773.

112. Kurakula K, Koenis DS, van Tiel CM, de Vries CJ. NR4A nuclear receptors are orphans but not lonesome. Biochim Biophys Acta. 2014; 1843(11):2543–55. https://doi.org/10.1016/j.bbapap.2014.06.010 PMID: 24975497.
113. He K, Dai ZY, Li PZ, Zhu XW, Gong JP. Association between liver X receptor-alpha and neuron-derived orphan nuclear receptor-1 in Kupffer cells of C57BL/6 mice during inflammation. Mol Med Rep. 2015; 12(4):6098–104. Epub 2015/08/05. https://doi.org/10.3892/mmr.2015.4155 PMID: 26239564.

114. Hamers AA, Uleman S, van Tiel CM, Kruijswijk D, van Stalborch AM, Huveneers S, et al. Limited role of nuclear receptor Nur77 in Escherichia coli-induced peritonitis. Infect Immun. 2014; 82(1):253–64. https://doi.org/10.1128/IAI.00721-13 PMID: 24166953; PubMed Central PMCID: PMCPMC3911847.

115. Saini A, Mahajan S, Ahuja N, Bhagyaraj E, Kalra R, Janmeja AK, et al. An Accord of Nuclear Receptor Expression in M. tuberculosis Infected Macrophages and Dendritic Cells. Scientific reports. 2018; 8(1):2296. https://doi.org/10.1038/s41598-018-20769-4 PMID: 29396519; PubMed Central PMCID: PMCPMC5797181.

116. Sutaria N, Liu CT, Chen TC. Vitamin D Status, Receptor Gene Polymorphisms, and Supplementation on Tuberculosis: A Systematic Review of Case-Control Studies and Randomized Controlled Trials. J Clin Transl Endocrinol. 2014; 1(4):151–60. https://doi.org/10.1038/jcte.2014.001 PMID: 25599020; PubMed Central PMCID: PMCPMC4295520.

117. Salamon H, Bruiners N, Lakehal K, Shi L, Ravi J, Yamaguchi KD, et al. Cutting edge: Vitamin D regulates lipid metabolism in Mycobacterium tuberculosis infection. Journal of immunology. 2014; 193(1):30–4. https://doi.org/10.4049/jimmunol.1400736 PMID: 24899504; PubMed Central PMCID: PMCPMC4073889.

118. Leon Rodriguez DA, Carmona FD, Gonzalez CI, Martin J. Evaluation of VDR gene polymorphisms in Trypanosoma cruzi infection and chronic Chagasic cardiomyopathy. Scientific reports. 2016; 6:31263. https://doi.org/10.1038/srep31263 PMID: 27502545.

119. Mubaraki MA, Dkhil MA, Hafiz TA, Khalil MF, Al-Shaebi EM, Delic D, et al. Vitamin D receptor regulates intestinal inflammatory response in mice infected with blood stage malaria. Microbial pathogenesis. 2018; 117:299–303. Epub 2018/03/03. https://doi.org/10.1016/j.micpath.2018.02.048 PMID: 29496525.

120. Whitcomb JP, Deagnostino M, Ballentine M, Fu J, Tenniswood M, Welsh J, et al. The Role of Vitamin D and Vitamin D Receptor in Immunity to Leishmania major Infection. J Parasitol Res. 2012; 2012:134645. Epub 2011/10/19. https://doi.org/10.1155/2012/134645 PMID: 22007288; PubMed Central PMCID: PMCPMC3191735.

121. Qiao E, Ji M, Wu J, Ma R, Zhang X, He Y, et al. Expression of the PXR gene in various types of cancer and drug resistance. Oncol Lett. 2013; 5(4):1093–100. https://doi.org/10.3892/ol.2013.1149 PMID: 23599746; PubMed Central PMCID: PMCPMC3628904.

122. Dubrac S, Elentner A, Ebner S, Horejs-Hoeck J, Schmuth M. Modulation of T lymphocyte function by the pregnane X receptor. Journal of immunology. 2010; 184(6):2949–57. https://doi.org/10.4049/jimmunol.0902151 PMID: 20173028.

123. Qiu Z, Cervantes JL, Ciçek BB, Mukherjee S, Venkatesh M, Maher LA, et al. Pregnane X Receptor Regulates Pathogen-induced Inflammation and Host Defense against an Intracellular Bacterial Infection through Toll-like Receptor 4. Scientific reports. 2016; 6:31936. Epub 2016/08/24. https://doi.org/10.1038/srep31936 PMID: 27550658; PubMed Central PMCID: PMCPMC4994038.

124. Sui Y, Xu J, Rios-Pilier J, Zhou C. Deficiency of PXR decreases atherosclerosis in apoE-deficient mice. J Lipid Res. 2011; 52(9):1652–9. https://doi.org/10.1194/jlr.M017376 PMID: 21685500; PubMed Central PMCID: PMCPMC3151685.

125. Bhagyaraj E, Nanduri R, Saini A, Dkhar HK, Ahuja N, Chandra V, et al. Human Xenobiotic Nuclear Receptor PXR Augments Mycobacterium tuberculosis Survival. Journal of immunology. 2016; 197(1):244–55. https://doi.org/10.4049/jimmunol.1600203 PMID: 27233963.

126. Chen Y, Tang Y, Guo C, Wang J, Boral D, Nie D. Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. Biochem Pharmacol. 2012; 83(8):1112–26. Epub 2012/02/14. https://doi.org/10.1016/j.bcp.2012.01.030 PMID: 22326308; PubMed Central PMCID: PMCPMC3339266.

127. Bhagyaraj E, Tiwari D, Ahuja N, Nanduri R, Saini A, Kalra R, et al. A human xenobiotic nuclear receptor contributes to nonresponsiveness of Mycobacterium tuberculosis to the antibacterials drug rifampicin. J Biol Chem. 2018; 293(10):3747–57. https://doi.org/10.1074/jbc.M117.81377 PMID: 29358328; PubMed Central PMCID: PMCPMC5846149.

128. Heelsley RN, Sui Y, Ai N, Park SH, Welsh WJ, Zhou C. Pregnane X receptor mediates dyslipidemia induced by the HIV protease inhibitor amprenavir in mice. Mol Pharmacol. 2013; 83(6):1190–9. Epub 2013/03/23. https://doi.org/10.1124/mol.112.085753 PMID: 23519392; PubMed Central PMCID: PMCPMC3657097.
129. Kojetin DJ, Burris TP. REV-ERB and ROR nuclear receptors as drug targets. Nat Rev Drug Discov. 2014; 13(3):197–216. https://doi.org/10.1038/nrd4100 PMID: 24577401; PubMed Central PMCID: PMC4865262.

130. Guillaume D, Dardente H, Giguere V, Cermakian N. Differential control of Bmal1 circadian transcription by REV-ERB and ROR nuclear receptors. J Biol Rhythms. 2005; 20(5):391–403. Epub 2005/11/04. https://doi.org/10.1177/0747730405277232 PMID: 16267379.

131. Gervois P, Chopin-Delannoy S, Fadel A, Dubois G, Kosykh V, Fruchart JC, et al. Fibrates increase human REV-ERBa expression in liver via a novel peroxisome proliferator-activated receptor response element. Mol Endocrinol. 1999; 13(3):400–9. Epub 1999/03/17. https://doi.org/10.1210/mend.13.3.0248 PMID: 10076997.

132. Raghuram S, Stayrook KR, Huang P, Rogers PM, Nosie AK, McClure DB, et al. Identification of heme as the ligand for the orphan nuclear receptors REV-ERBa and REV-ERBBeta. J Biol Chem. 1999; 274(23):15546–72. Epub 1999/06/08. https://doi.org/10.1074/jbc.274.23.15546 PMID: 10316260; PubMed Central PMCID: PMCPM215028.

133. Chandra V, Bhagyraj E, Nanduri R, Ahuja N, Gupta P. NR1D1 ameliorates Mycobacterium tuberculosis clearance through regulation of autophagy. Autophagy. 2015; 11(1):1987–97. https://doi.org/10.1080/15548627.2014.971100 PMID: 25300000; PubMed Central PMCID: PMC4389999.

134. Kim SY, Yang CS, Lee HM, Kim JK, Kim YS, Kim YR, et al. ESRRA (estrogen-related receptor alpha) is a key coordinator of transcriptional and post-translational activation of autophagy to promote innate host defense. Autophagy. 2018; 14(1):152–68. https://doi.org/10.1080/15548627.2017.1330051 PMID: 29841353; PubMed Central PMCID: PMC564864.

135. Sonoda J, Laganiere J, Mehl IR, Barish GD, Chong LW, Li X, et al. Nuclear receptor ERR alpha and coactivator PGC-1 beta are effectors of IFN-gamma-induced host defense. Genes Dev. 2007; 21(15):1909–20. https://doi.org/10.1101/gad.1553007 PMID: 17671090; PubMed Central PMCID: PMC1935029.

136. Giguere V. Transcriptional control of energy homeostasis by the estrogen-related receptors. Endocr Rev. 2008; 29(6):677–96. https://doi.org/10.1210/er.2008-0017 PMID: 18664618.

137. Yuki JM, Kim TS, Kim SY, Lee HM, Han J, Dufour CR, et al. Orphan Nuclear Receptor ERRalpha Controls Macrophage Metabolic Signaling and A20 Expression to Negatively Regulate TLR-Induced Inflammation. Immunity. 2015; 43(1):80–91. https://doi.org/10.1016/j.immuni.2015.07.003 PMID: 26200012.

138. Kim DK, Jeong JH, Lee JM, Kim KS, Park SH, Kim YD, et al. Inverse agonist of estrogen-related receptorgamma controls Salmonella typhimurium infection by modulating host iron homeostasis. Nat Med. 2014; 20(4):419–24. https://doi.org/10.1038/nm.3483 PMID: 24658075.

139. Han CY. Update on FXR Biology: Promising Therapeutic Target? Int J Mol Sci. 2018; 19(7). https://doi.org/10.3390/ijms19072069 PMID: 30013008; PubMed Central PMCID: PMC6073832.

140. Hao H, Cao L, Jiang C, Che Y, Zhang S, Takahashi S, et al. Farnesoid X Receptor Regulation of the NLRP3 Inflammasome Underlies Cholestasis-Associated Sepsis. Cell Metab. 2017; 25(4):856–67 e5. https://doi.org/10.1016/j.cmet.2017.03.007 PMID: 28380377.

141. Xie S, Guo C, Chi Z, Huang B, Wu Y, Wang D, et al. A rapid administration of GW4064 inhibits the NLRP3 inflammasome activation independent of farnesoid X receptor agonism. FEBS letters. 2017; 591(18):2836–47. https://doi.org/10.1002/1773-3468.12782 PMID: 28787755.

142. Schulman IG. Nuclear receptors as drug targets for metabolic disease. Adv Drug Deliv Rev. 2010; 62(13):1307–15. Epub 2010/07/27. https://doi.org/10.1016/j.addr.2010.07.002 PMID: 20693343; PubMed Central PMCID: PMC2987515.

143. Fan F, Hu R, Munzi A, Chen Y, Dunn RT, 2nd, Weik K, et al. Utilization of human nuclear receptors as an early counter screen for off-target activity: a case study with a compendium of 615 known drugs. FEBS letters. 2017; 591(18):2836–47. https://doi.org/10.1002/1773-3468.12782 PMID: 28787755.

144. Hoffmann BR, El-Mansy MF, Sem DS, Greene AS. Chemical proteomics-based analysis of off-target binding profiles for rosiglitazone and pioglitazone: clues for assessing potential for cardiotoxicity. J Med Chem. 2012; 55(19):8260–71. Epub 2012/09/14. https://doi.org/10.1021/jm301204r PMID: 22970990; PubMed Central PMCID: PMC4113394.